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Mammography is the only screening test known to reduce breast 
cancer mortality through the early detection of breast cancers 
(1,2). Breast biopsies are performed after 1%–2% of mammog-
raphy screenings when suspect areas on the mammograms cannot 
be explained by additional imaging (3). However, cancer is not 
detected in 65%–75% of these biopsies (4). Total biopsy rates are 
two to three times higher in the United States than in the United 
Kingdom, despite similar cancer detection rates (5). Such high 
rates of biopsy demand that women and their health-care providers 
understand the adverse effects, if any, so that women are better 
informed about the effects and potential risks (6–8).
Although it is reported that breast biopsy can cause architec-
tural changes in the breast, such as scarring and tissue distortion 
(9), it is unclear how these changes affect subsequent interpretive 
performance of screening mammography (10). One study reported 
that 3 years after a biopsy, 14% of the women had architectural 
distortion and 26% had skin distortion (11). Another study showed 
an association between previous breast surgery and reduced sensi-
tivity of screening mammography (12). However, the reported 
reduction in the latter study (12) was not statistically significant, 
and the investigators did not adjust for risk factors such as breast 
density and months since last mammogram that can potentially 
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 Background Most breast biopsies will be negative for cancer. Benign breast biopsy can cause changes in the breast tissue, 
but whether such changes affect the interpretive performance of future screening mammography is not 
known.
 Methods We prospectively evaluated whether self-reported benign breast biopsy was associated with reduced subse-
quent screening mammography performance using examination data from the mammography registries of the 
Breast Cancer Surveillance Consortium from January 2, 1996, through December 31, 2005. A positive interpre-
tation was defined as a recommendation for any additional evaluation. Cancer was defined as any invasive 
breast cancer or ductal carcinoma in situ diagnosed within 1 year of mammography screening. Measures of 
mammography performance (sensitivity, specificity, and positive predictive value 1 [PPV1]) were compared 
both at woman level and breast level in the presence and absence of self-reported benign biopsy history. 
Referral to biopsy was considered a positive interpretation to calculate positive predictive value 2 (PPV2). 
Multivariable analysis of a correct interpretation on each performance measure was conducted after adjusting 
for registry, year of examination, patient characteristics, months since last mammogram, and availability of 
comparison film. Accuracy of the mammogram interpretation was measured using area under the receiver op-
erating characteristic curve (AUC). All statistical tests were two-sided.
 Results A total of 2 007 381 screening mammograms were identified among 799 613 women, of which 14.6% mammo-
grams were associated with self-reported previous breast biopsy. Multivariable adjusted models for mammog-
raphy performance showed reduced specificity (odds ratio [OR] = 0.74, 95% confidence interval [CI] = 0.73 to 
0.75, P < .001), PPV2 (OR = 0.85, 95% CI = 0.79 to 0.92, P < .001), and AUC (AUC 0.892 vs 0.925, P < .001) among 
women with self-reported benign biopsy. There was no difference in sensitivity or PPV1 in the same adjusted 
models, although unadjusted differences in both were found. Specificity was lowest among women with docu-
mented fine needle aspiration—the least invasive biopsy technique (OR = 0.58, 95% CI = 0.55 to 0.61, P < .001). 
Repeating the analysis among women with documented biopsy history, unilateral biopsy history, or restricted 
to invasive cancers did not change the results.
 Conclusions Self-reported benign breast biopsy history was associated with statistically significantly reduced mammog-
raphy performance. The difference in performance was likely because of tissue characteristics rather than the 
biopsy itself.
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confound the association (13,14). A history of previous biopsy 
could also be associated with a higher mammography sensitivity 
because radiologists lower their threshold to call an examination 
abnormal. However, a prior benign biopsy may not only change 
subsequent interpretive sensitivity, it may also reduce specificity 
and therefore increase the likelihood of a subsequent false-positive 
test (6,15).
In this study, we evaluated the association between benign 
biopsies and future mammography interpretive performance using 
the large database of the Breast Cancer Surveillance Consortium 
(BCSC) (16). Our study also accounted for demographic and 
mammography characteristics associated with interpretive perfor-
mance to determine the possible consequences of benign biopsy. 
We sought more precise estimates of screening mammography 
interpretive performance compared with previous reports (12) 
because we had a large number of cancer cases, data resources for 
prospective association between biopsy history and subsequent 
interpretation, and cancer occurrence.
Methods
Study Design
The purpose of our study was to evaluate the association between 
benign biopsies and future mammography interpretive perfor-
mance. We used the radiologists’ interpretations to calculate four 
measures that reflect the accuracy of mammography interpretive 
performance—two fundamental characteristics of a test (sensitivity 
and specificity), and two measures that are commonly monitored 
in clinical practice by the radiologists—positive predictive value 1 
(PPV1) and positive predictive value 2 (PPV2). The measures are 
defined as follows: 1) sensitivity—the likelihood of a positive mam-
mogram when cancer is present, 2) specificity—the likelihood of a 
negative mammogram when cancer is absent, 3) PPV1—the pro-
portion of screening mammograms associated with cancer among 
all screening mammograms recommended for any additional eval-
uation, and 4) PPV2—the proportion of screening mammograms 
associated with cancer among all screening mammograms recom-
mended for biopsy. We calculated a fifth characteristic (area under 
the receiver operating characteristic curve [AUC]) that reflects the 
overall accuracy of the radiologist’s interpretations (17,18) and 
have defined it below.
For each performance measure that was used in the main 
analysis, we counted a woman as having cancer if ductal carcinoma 
in situ (DCIS) or invasive cancer was diagnosed within 1 year of the 
screening mammogram. If cancer was detected by a second 
screening mammogram performed between 9 and 12 months of the 
first mammogram, then the cancer was associated with the second 
mammogram. The study design is summarized in Figure 1.
Data on women’s health history were collected by a survey at 
the time of each mammogram at the participating radiology facil-
ities of the BCSC (16). We used breast biopsy history from this 
survey as our measure of biopsy exposure in the main analysis and 
evaluated the validity of our findings in secondary analyses of a 
subset of women who had documented biopsies. We hypothesized 
that changes in the breast tissue after a benign biopsy would reduce 
both sensitivity and specificity and thus reduce the overall accu-
racy. We further hypothesized that the quantity of breast tissue 
cONteXt AND cAVeAtS
Prior knowledge
Breast biopsy is performed on women if additional imaging cannot 
explain a suspect finding detected on a mammogram, and about 
65%–75% of the biopsies are negative for cancer. However, it is not 
known whether a benign breast biopsy affects future screening 
mammography interpretive performance.
Study design
Multivariable analyses at the woman level and at the breast level 
included 2 007 381 screening mammograms to examine the associ-
ation between biopsy history (self-reported and/or documented) 
and mammography interpretive performance by the radiologists. 
Data from mammography registries and the pathology database of 
the Breast Cancer Surveillance Consortium were used and linked 
with regional cancer registries for breast cancer occurrence.
Contribution
Self-reported biopsy history was associated with reduced accuracy 
of mammography interpretive performance. The difference in 
performance was likely because of breast tissue characteristics 
and not the biopsy technique.
Implications
The results may help clinicians to inform women about the poten-
tial risks of benign biopsy.
Limitations
Mammography interpretive performance may be influenced by 
breast tissue characteristics that prompt a benign biopsy, as well as 
the biopsy itself, and their effects cannot be completely separated.
From the Editors
 
removed at the time of a biopsy would affect the screening mam-
mography performance, so sensitivity would be lowest after an 
excisional biopsy and still reduced, but to a lesser extent, after a 
core biopsy.
Setting
We used data from the mammography registries of the BCSC, 
which are funded by the National Cancer Institute (NCI), to link 
reports of radiologists’ mammography interpretations with docu-
mentation of cancer occurrence in regional population-based 
cancer registries (http://breastscreening.cancer.gov/) (16). The 
mammography registries consist of the mammography facilities at 
the Group Health of Puget Sound in Washington, San Francisco 
Bay Area (California), Albuquerque (New Mexico), New Hampshire, 
Vermont, and 39 counties of North Carolina. Cancer occurrence 
data were collected from population-based cancer registries 
between January 2, 1996, and December 31, 2006. For analyses 
based on tissue, biopsy data were collected from the BCSC 
pathology database covering the populations served by the mam-
mography registries of the BCSC (16). The BCSC pathology 
database contains information from the available pathology reports 
of the participating hospitals. The majority of the pathology 
reports are for biopsies done in 1995 or later; however, there are 
some reports also from earlier years. All mammography registries 
regularly sent common data elements and the cancer status of 
women to the Statistical Coordinating Center (SCC) of the BCSC 
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for pooled analyses. Each mammography registry and the SCC 
received approval by the institutional review board for either active or 
passive consent process, waiver of consent to enroll participants, link 
data, and perform analytic studies. The SCC also received a federal 
Certificate of Confidentiality. All procedures were compliant with the 
Health Insurance Portability and Accountability Act. All registries 
and the SCC have protections for the identities of the women, 
physicians, and facilities who participated in this research (19).
Subjects
The study included screening mammograms from January 2, 1996, 
through December 31, 2005, for asymptomatic women aged 40–89 
years who reported their biopsy history at the time of the mam-
mography examination. Screening mammograms were defined as 
bilateral examinations that the radiologist coded as “screening” 
among women without any breast imaging within the previous 
9 months. We included screening mammograms through December 
31, 2005, to allow at least 1 year of follow-up to identify their 
cancer status (no breast cancer, invasive breast cancer, DCIS). We 
excluded mammograms from women with a history of breast 
cancer, previous breast surgery (mastectomy or lumpectomy for 
treatment of breast cancer, breast reconstruction, breast augmen-
tation or reduction), or if the women reported breast symptoms at 
the time of screening mammography examination.
Measurements
Mammography Interpretations. The analytic dataset included 
the radiologist’s initial interpretation based on two mammo-
graphic views and the final interpretation after completion of 
Figure 1. Study design showing the source of 
the observational data for the main and sec-
ondary analyses. DCIS = ductal carcinoma in 
situ; PPV1 = positive predictive value 1; PPV2 = 
positive predictive value 2.
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additional breast imaging within 6 months. Tumors are most 
commonly missed at the initial interpretation, and scarring after 
a biopsy could affect the likelihood of the radiologist recom-
mending additional imaging (recall) (20). Therefore, the initial 
interpretation was used to calculate sensitivity, specificity, PPV1, 
and overall accuracy (AUC). The final interpretation was used to 
calculate PPV2 because it is a commonly monitored measure (21). 
Radiologists recorded all interpretations using the American 
College of Radiology Breast Imaging Reporting and Data System 
(BI-RADS) assessment (0 = needs additional imaging, 1 = normal, 
2 = benign finding, 3 = probably benign finding, 4 = suspicious 
abnormality, 5 = highly suggestive of malignancy) (17). Consistent 
with earlier work, BI-RADS 1, 2, or 32 (3 without a recommen-
dation for immediate work-up or imaging) was considered a 
negative interpretation, and BI-RADS 0, 3+ (3 in association with 
a recommendation for immediate work-up or imaging), 4, or 5 
was defined as a positive interpretation (P1) (14,22). After addi-
tional imaging, we used BI-RADS 4 or 5 as a positive interpreta-
tion (P2) in the calculation of PPV2 (23).
Mammography Performance. Based on the initial BI-RADS as-
sessment, and whether women were diagnosed with DCIS or inva-
sive cancer within 1 year, we classified each initial mammography 
interpretation as a true positive (TP1), false positive (FP1), true 
negative (TN1), or false negative (FN1) (14,18). To calculate the 
mammography performance based on the final BI-RADS assess-
ment, we considered the interpretation after additional imaging 
was completed, and BI-RADS 4 and 5 were classified as positive 
interpretations. We calculated mammography performance 
measures based on the initial BI-RADS assessment as follows: 
sensitivity = TP1/(TP1 + FN1), specificity = TN1/(FP1 + TN1), 
and PPV1 = TP1/(FP1 + TP1). We calculated PPV2 based on the 
final interpretation, and a recommendation for biopsy was consid-
ered to be a positive interpretation. We determined the number of 
women with cancer and a recommendation for biopsy (TP2) and 
the number of women without cancer among those recommended 
for biopsy (FP2). PPV2 was calculated as TP2/(FP2 + TP2).
Biopsy History. At the time of each screening mammogram, 
women were asked whether they had one of the several breast 
procedures (fine needle or cyst aspiration, biopsy, lumpectomy, 
mastectomy, breast reduction, or breast implants) before screening. 
The type of biopsy was not always ascertained in self-reports, and 
in some years, at least two of the mammography facilities did not 
distinguish fine needle aspiration (FNA) from needle biopsy; 
therefore, women reporting FNA and cyst aspiration were in-
cluded as biopsied women. In this study, women reporting a pre-
vious biopsy at the time of screening were designated as “biopsied” 
women, and those reporting no previous biopsy were designated as 
“unbiopsied” women. Biopsies were classified as benign if they 
were reported by women who did not have a breast cancer history 
and did not appear in the registry as having had breast cancer 
before the survey date. The main analysis of the association 
between biopsy history and sensitivity, specificity, PPV1, and 
AUC was performed using self-reported breast biopsy.
A secondary analysis of the association between biopsy history 
and the performance measures was performed using biopsies that 
were recorded in the BCSC pathology database. If a woman had 
more than one biopsy recorded in the pathology database before a 
specific mammography examination, the type of biopsy was classi-
fied based on the most invasive procedure (FNA<core<excisional). 
A woman reporting all three biopsy types was classified under 
excisional biopsy.
Statistical Analyses
Overview. The association between biopsy history and mammog-
raphy interpretive performance was examined in two main multi-
variable analyses—one for the woman as a whole (woman level) 
and the other for the affected breast (breast level). In the main 
analysis, we classified women as having cancer if they had either 
invasive breast cancer or DCIS. In a secondary analysis, we 
excluded women with DCIS to see if it affected our results. We 
considered that the effect of biopsy could be different for the two 
cancer types because DCIS is more likely than invasive cancer to be 
calcified and therefore more easily visible despite tissue changes.
Mammograms missing one or more of the following variables 
were removed from the multivariable analyses because we thought 
they might confound the associations between biopsy and inter-
pretive performance or were the exposure of interest—BI-RADS 
mammographic breast density, months since last mammogram, 
presence of comparison films at the time of interpretation, and 
biopsy history. Among the 2 362 650 eligible mammograms, 
355 269 mammograms were excluded—116 555 mammograms 
without BI-RADS mammographic breast density, 91 723 mammo-
grams without information on months since last mammogram, 
22 096 mammograms where it was unknown if comparison films 
were available, and 124 895 mammograms from women who did 
not report their biopsy history. Among the mammograms excluded 
because of missing data, the age distribution was similar to those 
retained for the multivariable analyses. After removing all 
screening mammograms with missing values, 85.0% (2 007 381) of 
the eligible screening mammograms were included in the main 
multivariable analyses (Figure 1).
Woman-Level Analysis. The main multivariable analysis at the 
woman level was performed using 2 007 381 mammograms from 
799 613 women (Figure 1) to evaluate the association between 
benign biopsy history and mammography interpretive perfor-
mance. Radiologists record one BI-RADS assessment for each 
breast. To classify an interpretation in the woman-level analyses, 
we used the higher of the two BI-RADS assessments for each 
screening examination. We also repeated analyses of the associa-
tions between biopsy history and sensitivity, specificity, PPV1, 
and AUC using biopsies documented in the pathology database. 
As a result, we included 1 703 328 screening examinations with-
out a previous biopsy, 43 910 screening examinations with a 
documented previous biopsy, and 262 571 screens with a self-
reported previous biopsy that was not documented in the pathology 
database. Because we used both documented and self-reported 
biopsies, there were more screening mammograms (2 009 809) 
than the main analysis that relied on the self-reported biopsies 
alone. We further evaluated the association between the type of 
biopsy and mammography interpretive performance by also 
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including the 43 910 screens with a documented previous biopsy 
(Figure 1).
Breast-Level Analysis. Because biopsies could be done in either 
breast and at one or more locations within the breast, the associa-
tions between the interpretation and subsequent cancer occurrence 
could be inaccurate at the woman level if a self-reported biopsy 
occurred in a different breast than the subsequent cancer (misattri-
bution). Furthermore, there could be adverse selection among 
women with a false-negative biopsy such that they are more likely 
to seek care from a new provider who might not be captured in the 
registry. Finally, we were concerned that the breast parenchymal 
pattern that led to a negative breast biopsy could also affect subse-
quent performance (parenchymal confounding). Therefore, we 
performed an analysis of the association between breast biopsy and 
interpretive performance on screening mammography at the 
breast level within women with a subsequent cancer.
The breast-level analysis evaluated interpretive performance 
based on the breast-specific BI-RADS interpretation, cancer out-
come, and biopsy history for each breast (breast level) in 253 543 
examinations with a self-reported history of a previous unilateral 
(one breast) benign breast biopsy. Each woman had two BI-RADS 
assessments at the time of each examination. Any cancer that 
occurred subsequently was associated with the specific breast in 
which it occurred. The sensitivity analysis compared interpretive 
performance in breasts with or without biopsy history in women 
who developed breast cancer. The specificity analysis compared 
interpretive performance in the biopsied and unbiopsied breasts 
without cancer. By conducting the breast-level analysis within 
women, we avoid adverse selection and mitigate the problem of 
misattribution because the effect of biopsy and cancer are associ-
ated in the same breast. We also mitigate the problem of parenchy-
mal confounding to the extent that breast patterns are bilateral, 
and therefore, their effect on interpretive performance is similar in 
the biopsied and unbiopsied breasts.
The breast-level analysis was repeated using an additional 
25 845 mammography examinations with previous unilateral 
biopsy documented in the pathology database. This independent 
analysis was performed to again evaluate whether the findings 
based on self-reported biopsy differed from the findings based on 
documented biopsy.
Regression Models. Logistic regression models were used to 
examine the association between self-reported biopsy history and 
each performance measure after accounting for differences across 
registries and patient characteristics influencing mammography 
interpretive performance. A separate logistic regression model 
was fit for each measure of performance to compute the odds of a 
correct interpretation among examinations in women reporting a 
biopsy history, compared with examinations among women who did 
not report such a history: 1) sensitivity—odds of a positive screen 
(BI-RADS assessment = 0, 4, 5, or 3 with immediate work-up) 
given a cancer diagnosis among women with a biopsy history 
compared with women without a history, 2) specificity—odds of a 
negative screen (BI-RADS assessment = 1, 2, or 3 without imme-
diate work-up) given no cancer diagnosis among women with a 
biopsy history compared with women without a history, 3) 
PPV1—odds of a cancer given a positive screen (BI-RADS assess-
ment = 0, 4, 5, or 3 with immediate work-up) (PPV1) among 
women with a biopsy history compared with women without a 
history, and 4) PPV2—odds of a cancer given biopsy recommenda-
tion (BI-RADS assessment = 4, 5) (PPV2) among women with a 
biopsy history compared with women without a history. All analyses 
included year of mammogram and mammography registry as covari-
ates and accounted for the following patient characteristics—age 
in 5-year intervals (14), BI-RADS breast density (1 = almost en-
tirely fat, 2 = scattered fibroglandular, 3 = heterogeneously dense, 
4 = extremely dense) (13,24), months since last mammography 
(no mammogram within past 59, 9–11, 12–35, 36–59) months (14), 
and the availability of a comparison film (no, yes) (25). To test the 
specific effects of race, we also performed an additional analysis of 
each performance measure testing for the effect of biopsy within 
race (white, non-Hispanic, black non-Hispanic, Asian/Pacific 
Islander, American Indian/Alaska Native, Other/mixed, and 
Hispanic) and then tested an interaction term between race and 
history of biopsy. We did not include family history because it has 
not been associated with differential mammography performance 
(25). The logistic regression models were fit using the SAS proce-
dure GENMOD (26). Although multiple examinations can be in-
cluded for a single woman in the analyses of specificity and PPV, 
we chose not to account for the inherent correlation between 
observations using a generalized estimating equations approach 
because such an approach did not change the conclusions in a 
previous study in a large sample of women (27), and a study by 
Njor et al. (28) also demonstrated the independence of mammo-
graphic examinations. All two-sided P values less than .05 were 
considered statistically significant.
Receiver Operating Characteristic Analysis. We conducted a re-
ceiver operating characteristic (ROC) analysis to examine the effect 
of “self-reported biopsy history,” “documented biopsy history,” and 
“no reported biopsy” on overall accuracy by estimating the area under 
the ROC curve (AUC). We used ordinal regression to fit an ROC 
model that adjusted for the following covariates—mammography 
registry, age at mammogram, breast density, months since last 
mammogram, presence of a comparison film, and year of mammo-
gram. For this analysis, we used the initial interpretation and the 
following ordinal scale for the BI-RADS interpretations: 1, 2, 3 
without additional evaluation; 3 with additional evaluation; and 0, 4, 5. 
The ROC analysis was fit using the SAS procedure NLMIXED 
(18,22). We compared the area under the ROC curve (AUC) for 
mammograms with a self-reported biopsy history and the AUC for 
those without such a history to determine whether self-reported 
biopsy history was associated with overall accuracy of perfor-
mance. Likelihood ratio statistics were used to determine whether 
the AUCs were statistically significantly different. All two-sided 
P values less than .05 were considered statistically significant.
results
Overview
We identified a total of 2 007 381 eligible screening mammograms 
among 799 613 women between January 2, 1996, and December 
31, 2005. Among these mammograms, 9065 were associated with 
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breast cancer detected within 1 year of screening. The mammo-
grams were obtained from women who were 75.9% white non-
Hispanic, 6.4% black non-Hispanic, 2.7% Asian, 0.7% American 
Indian/Alaska Native, 1.1% Other/mixed (two or more races), 7% 
unknown race, and 6.3% of Hispanic ethnicity. Within 1 year of a 
screening mammogram, 7109 women were diagnosed with inva-
sive breast cancer (5635 among previously unbiopsied women, 
1474 among previously biopsied women), and 1956 with DCIS 
(1546 among previously unbiopsied women, 410 among previously 
biopsied women).
The characteristics of the women at the time of screening 
mammograms are shown in Table 1. The characteristics were 
compared among mammography examinations with and without a 
prior benign breast biopsy and included age, breast density, 
months since last mammogram, presence of a comparison film, 
initial interpretation, and year at the time of the mammogram. 
Table 1 includes the screening mammograms from women who 
reported a prior benign biopsy at the time of the examination, and 
they accounted for 14.6% (n = 293 100) of all screening mammo-
grams (N = 2 007 381). Women received between 1 and 10 
screening mammograms in the analytic dataset; the mean and me-
dian numbers of mammograms were 2.5 and 2.0, respectively (data 
not in table). Compared with examinations in women who did not 
report a prior benign breast biopsy, examinations in women who 
reported a prior benign breast biopsy were more likely to be 
among those aged 50 years or older (P < .001), with increased 
Table 1. Description of women’s characteristics by self-reported history of breast biopsy or aspiration at the time of 2 007 381 Breast 
Cancer Surveillance Consortium (BCSC) screening mammograms*
Women and mammogram characteristics
No history of breast  
biopsy or aspiration  
(n = 1 714 281)
Self-reported history  
of breast biopsy or  
aspiration (n = 293 100)
Total screening 
examinations  
(n = 2 007 381)
n (%) n (%) n (%)
Age group, y†
 40–44 263 154 (15.4) 23 352 (8.0) 286 506 (14.3)
 45–49 284 425 (16.6) 37 293 (12.7) 321 718 (16.0)
 50–54 299 837 (17.5) 49 928 (17.0) 349 765 (17.4)
 55–59 236 287 (13.8) 47 751 (16.3) 284 038 (14.1)
 60–64 181 755 (10.6) 39 225 (13.4) 220 980 (11.0)
 65–69 154 151 (9.0) 33 588 (11.5) 187 739 (9.4)
 70–74 130 877 (7.6) 28 332 (9.7) 159 209 (7.9)
 75–89 163 795 (9.6) 33 631 (11.5) 197 426 (9.8)
Density†
 Almost entirely fat 155 682 (9.1) 16 823 (5.7) 172 505 (8.6)
 Scattered fibroglandular 797 857 (46.5) 119 337 (40.7) 917 194 (45.7)
 Heterogeneously dense 642 462 (37.5) 128 957 (44.0) 771 419 (38.4)
 Extremely dense 118 280 (6.9) 27 983 (9.6) 146 263 (7.3)
Months since last mammogram†
 No mammogram within past 59 months 171 446 (10.0) 10 566 (3.6) 182 012 (9.1)
 9–11 25 717 (1.5) 6240 (2.1) 31 957 (1.6)
 12–35 1 392 465 (81.2) 262 104 (89.4) 1 654 569 (82.4)
 36–59 124 653 (7.3) 14 190 (4.8) 138 843 (6.9)
Comparison film†
 No 255 550 (14.9) 28 472 (9.7) 284 022 (14.1)
 Yes 1 458 731 (85.1) 264 628 (90.3) 1 723 359 (85.9)
Initial BI-RADS assessment†
 1 (Normal) 1 255 593 (73.2) 182 938 (62.4) 1 438 531 (71.7)
 2 (Benign finding) 291 913 (17.0) 74 147 (25.3) 366 060 (18.2)
 3 (Probably benign finding)‡ 21 833 (1.3) 4023 (1.4) 25 856 (1.3)
 3+ (Probably benign finding with immediate work-up)‡ 6891 (0.4) 1359 (0.5) 8250 (0.4)
 0 (Needs additional imaging) 132 453 (7.7) 29 351 (10.0) 161 804 (8.1)
 4 (Suspicious abnormality) 4963 (0.3) 1178 (0.4) 6141 (0.3)
 5 (Highly suggestive of malignancy) 635 (0.0) 104 (0.0) 739 (0.0)
Year of mammogram
 1996–1997 191 773 (11.2) 31 340 (10.7) 223 113 (11.1)
 1998–1999 339 844 (19.8) 49 158 (16.8) 389 002 (19.4)
 2000–2001 431 586 (25.2) 65 160 (22.2) 496 746 (24.7)
 2002–2003 469 288 (27.4) 90 769 (31.0) 560 057 (27.9)
 2004–2005 281 790 (16.4) 56 673 (19.3) 338 463§ (16.9)
* Frequency distributions for each woman and mammogram characteristics computed for screening mammograms without a self-reported biopsy history or with a 
self-reported biopsy history and for the total of both. BI-RADS = Breast Imaging Reporting and Data System.
† All distributions differ statistically significantly between women with and without a biopsy history; P < .001, based on x2 test (two-sided).
‡ We separated the BI-RADS category 3 interpretations into those without and with a recommendation for additional evaluation (BI-RADS 3 and 3+, respectively).
§ The drop in number of screening examinations was because of a loss of data from a site that left the BCSC.
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breast density (P < .001), had a mammogram performed in the past 
5 years (P < .001), and had comparison films available (90.3% vs 
85.1%, P < .001). Approximately, 90.9% of the mammograms were 
preceded by a mammogram in the past 59 months, and approxi-
mately 84.0% of all mammograms were within the past 35 months 
(Table 1). Mammography recall for additional evaluation (all 
interpretations >BI-RADS 3 with immediate work-up) was more 
likely when a benign biopsy history was reported, compared with 
those without such a history (10.9% vs 8.4%, P < .001). A total of 
0.3% (6880 of 2 007 381) screening mammograms were associated 
with a recommendation for biopsy (BI-RADS 4 or 5) (Table 1). 
Among the documented biopsies performed before screening 
mammography, the proportion of core biopsies increased steadily 
from 34.8% in 1996 to 71.8% in 2003 (data not shown).
Woman-Level Analysis
The radiologists’ unadjusted performance measures for screening 
mammography in women with and without a benign biopsy his-
tory at the time of the examination are shown in Table 2. Also 
shown are the adjusted odds ratios (ORs) for a correct mammog-
raphy interpretation in association with a benign biopsy history. 
A mammogram in a woman without a reported benign biopsy was 
always the referent. Unadjusted mammography sensitivity and 
specificity were lower for examinations in women reporting a 
biopsy at the time of a mammogram. After adjustment for age in 
5-year intervals, BI-RADS breast density, presence of a compar-
ison film, mammography registry, year of mammogram, and 
months since previous mammogram, mammography specificity 
and PPV2 were statistically significantly reduced (P < .001) for 
examinations associated with a history of a previous benign breast 
biopsy (Table 2).
The year of the mammogram was associated with mammog-
raphy performance (P < .05) in the multivariable models for all 
performance measures except PPV2, but the interaction between 
year of the mammogram and self-reported biopsy was only statis-
tically significant for specificity (data not shown). We therefore 
kept year of the mammogram in the multivariable model but 
excluded the interaction term for year of mammogram and self-
reported biopsy.
When we examined the effect of race on the association 
between previous benign biopsy and mammography interpretive 
performance, we found that biopsy history was not associated with 
differential effects across racial groups for sensitivity and PPV1 (P = 
.44 and P = .56, respectively) but it was associated with specificity 
(P < .001). Across all racial groups, the odds of a negative mammo-
gram when no cancer was diagnosed were always lower in women 
with a biopsy history (OR = 0.67–0.87), compared with women 
without such a history, and race was associated with statistically 
significant differences in specificity (P < .001) (data not shown in 
Table 2).
Breast-Level Analysis
The breast-level analysis confirmed the findings of the woman-
level analysis. The direction of association between biopsy history 
and the outcome of interest for each performance measure was the 
same. There were 253 543 screening mammograms among women 
reporting a unilateral biopsy history; 774 cancers subsequently 
occurred in an unbiopsied breast and 841 cancers in a biopsied 
Table 2. Mammography performance measures and the adjusted odds ratios comparing screening mammograms with a self-reported 
biopsy history to screening mammograms without a self-reported biopsy history*
Mammography  
performance measures
Unadjusted measures (95% CI) Adjusted OR
No biopsy Biopsy
Difference between no  
biopsy and biopsy  
(95% CI of difference) OR* (95% CI) P†
Sensitivity 82.3 (81.4 to 83.2) 79.6 (77.7 to 81.4) 2.70 (0.7 to 4.75) 0.88‡ (0.77 to 1.01) .0597
Specificity 91.9 (91.8 to 91.9) 89.5 (89.4 to 89.6) 2.30 (2.21 to 2.45) 0.74§ (0.73 to 0.75) <.0001
PPV1 4.1 (4 to 4.2) 4.7 (4.5 to 4.9) 20.60 (20.86 to 20.36) 1.01║ (0.95 to 1.07) .8213
PPV2 25.4 (24.8 to 26.1) 25.4 (24.2 to 26.7) 0.02 (21.34 to 1.38) 0.85¶ (0.79 to 0.92) <.0001
* Odds ratios (ORs) and 95% confidence intervals (CIs) for a correct interpretation comparing screening mammograms with a self-reported biopsy history with 
screening mammograms without a self-reported biopsy history were computed from multivariable logistic regression models including age at mammogram (in 
5-year intervals), months since last mammogram, breast density, availability of comparison film, mammography registry, and year of examination as covariates. 
Examinations not associated with a biopsy history (no biopsy) were the referent group and included 1 714 281 screens (7181 screens were associated with  
subsequent breast cancer). A total of 293 100 screening mammograms with a self-reported biopsy history were also included (1884 screens were associated 
with subsequent breast cancer). PPV1 = positive predictive value 1; PPV2 = positive predictive value 2.
† Two-sided P values for overall association of biopsy history with mammography performance measure, calculated using likelihood ratio tests.
‡ Odds of a positive screen (Breast Imaging Reporting and Data System [BI-RADS] = 0, 4, 5, or 3 with recommendation for additional evaluation) among screening 
mammograms from women with a subsequent cancer diagnosis (sensitivity), comparing screening mammograms from women with a biopsy history with 
screening mammograms from women without a biopsy history.
§ Odds of a negative screen (BI-RADS assessment = 1, 2, or 3 without recommendation for additional evaluation) among screening mammograms from women 
without a subsequent cancer diagnosis (specificity), comparing screening mammograms from women with a biopsy history with screening mammograms from 
women without a biopsy history.
║ Odds of a subsequent cancer among positive screening mammograms (BI-RADS = 0, 4, 5, or 3 with immediate work-up) (PPV1), comparing screening  
mammograms from women with a biopsy history with screening mammograms from women without a biopsy history.
¶ Odds of a subsequent cancer among screening mammograms with a recommendation for biopsy (BI-RADS = 4 or 5) (PPV2), comparing screening mammograms 
from women with a biopsy history with screening mammograms from women without a biopsy history.
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breast. The adjusted odds of the appropriate interpretation for 
each performance measure were reduced for women with a pre-
vious biopsy history, compared with women with no previous bi-
opsy: sensitivity (OR = 0.92, 95% confidence interval [CI] = 0.71 
to 1.19), specificity (OR = 0.90, 95% CI = 0.88 to 0.92), PPV1 (OR = 
0.97, 95% CI = 0.86 to 1.09), and PPV2 (OR = 0.84, 95% CI = 
0.72 to 0.98). Similar to the woman-level analysis, the breast-level 
adjusted analysis showed a statistically significantly reduced association 
between biopsy history and performance for mammography speci-
ficity (P < .001) and PPV2 (P = .025) (data not shown in tables 2–4).
The analysis using documented benign biopsy also confirmed 
the woman-level analysis. There were 43 910 screening mammo-
grams among women with a biopsy history documented in the 
BCSC pathology database, and 306 women developed cancer. 
Only a self-reported benign biopsy history was present in 262 571 
women, including 1667 women who developed cancer (Figure 1 and 
Table 3). Screening mammography performance after documented 
benign biopsies was associated with statistically significantly lower 
specificity (P < .001), PPV1 (P < .05), and PPV2 (P < .001) (Table 3). 
Cancer rates were lowest for women with no biopsy history (4.2 of 
1000), compared with women with a self-reported biopsy history 
(6.3 of 1000) and documented biopsy history (7.0 of 1000) (data not 
shown in tables 2–4). PPV1 was slightly elevated for screening 
mammograms performed after documented biopsies, and this was 
also consistent with the analysis using self-reported biopsy history 
(Table 3).
After excluding 1962 women with DCIS from the analysis, our 
conclusions that only specificity and PPV2 were statistically signif-
icantly lower among women with self-reported (or documented) 
previous benign biopsies remained unchanged (data not shown in 
tables 2–4). The odds ratios for a correct interpretation when no 
cancer was present (specificity) were 0.64 (95% CI = 0.62 to 0.66) 
for a documented previous biopsy and 0.75 (95% CI = 0.74 to 0.76) 
for a self-reported previous biopsy. The odds ratios for a recom-
mendation for biopsy (PPV2) were 0.74 (95% CI = 0.61 to 0.89) 
for a documented previous biopsy and 0.85 (95% CI = 0.78 to 0.93) 
for a self-reported previous biopsy history.
When we repeated the logistic regression analysis using mam-
mography examinations associated with documented biopsies and 
the types of biopsies performed, we found that compared with 
women with no previous biopsies, mammography specificity was 
statistically significantly reduced for all types of previous biopsies 
(Table 4). Specificity was lowest for women with previous FNAs or 
cyst aspirations. Women with previous core biopsies had a statisti-
cally significantly higher PPV1 but lower PPV2 compared with 
women without any previous biopsy (Table 4). The odds ratio of 
the adjusted sensitivity of a subsequent mammogram was higher 
among women with core and excisional biopsies but lower among 
those with FNA history, compared with women with no previous 
biopsies; however, these differences were not statistically signifi-
cant for sensitivity as shown in the adjusted model (Table 4).
In the breast-level analysis, we observed that 25 845 mammog-
raphy screenings among women with one previous documented 
unilateral benign breast biopsy were associated with 99 subsequent 
cancers in the biopsied breast and 90 cancers in the unbiopsied 
breast. Unadjusted mammography performance measures were 
lower in the breast with previous documented biopsy, and they 
remained statistically significantly reduced for specificity after 
Table 3. Association between documented vs self-reported breast biopsy history and subsequent screening mammography  
performance measures*
Mammography performance measures
Documented breast biopsy†  
(n = 43 910 screens),† OR (95% CI)
Self-reported breast biopsy only‡  
(n = 262 571 screens),‡ OR (95% CI) P§
Sensitivity║ 1.1 (0.82 to 1.53) 0.9 (0.75 to 0.99) .0765
Specificity¶ 0.64 (0.62 to 0.66) 0.75 (0.74 to 0.76) <.001
PPV1# 1.18 (1.03 to 1.34) 0.99 (0.93 to 1.05) <.05
PPV2** 0.78 (0.66 to 0.92) 0.87 (0.80 to 0.94) <.001
* Odds ratios (ORs) and 95% confidence intervals (CIs) for a correct interpretation when comparing screening mammograms with a biopsy history with screening 
mammograms without a biopsy history were computed from multivariable logistic regression models including age at mammogram (in 5-year intervals), months 
since last mammogram, breast density, availability of comparison film, mammography registry, and year of examination as covariates. The referent group 
included 1 703 328 mammography screenings among women without a breast biopsy, of which 7119 were associated with a subsequent breast cancer. PPV1 = 
positive predictive value 1; PPV2 = positive predictive value 2.
† Benign biopsies were documented in the cancer registries or pathology databases before mammograms performed from January 2, 1996, through December 
31, 2005 (306 screens were associated with a subsequent cancer in a woman).
‡ Screens with self-reported previous biopsy history but have no previous biopsy documented in the pathology database (1667 screens were associated with 
subsequent breast cancer).
§ Two-sided P values for overall association of biopsy history with mammography performance measure were calculated using likelihood ratio tests.
║ Odds of a positive screen (Breast Imaging Reporting and Data System [BI-RADS] = 0, 4, 5, or 3 with recommendation for additional evaluation) among  
screening mammograms from women with a subsequent cancer diagnosis (sensitivity), comparing screening mammograms from women with a biopsy  
history (documented or only self-reported) with screening mammograms from women without a biopsy history.
¶ Odds of a negative screen (BI-RADS assessment = 1, 2, or 3 without recommendation for additional evaluations) among screening mammograms from women 
without a subsequent cancer diagnosis (specificity), comparing screening mammograms from women with a biopsy history (documented or only self-reported) 
with screening mammograms from women without a biopsy history.
# Odds of a subsequent cancer among positive screening examinations (BI-RADS = 0, 4, 5, or 3 with recommendation for additional evaluation) (PPV1), com-
paring screening mammograms from women with a biopsy history (documented or only self-reported) with screening mammograms from women without a 
biopsy history.
**  Odds of a subsequent cancer among screening mammograms with a recommendation for biopsy (BI-RADS assessment = 4,5) (PPV2), comparing screening 
mammograms from women with a biopsy history (documented or only self-reported) with screening mammograms from women without a biopsy history.
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adjustment (OR = 0.82, 95% CI = 0.77 to 0.87, P < .001). The odds 
ratios of PPV1 (OR = 0.90, 95% CI = 0.65 to 1.23, P = .51) and 
PPV2 (OR = 0.75, 95% CI = 0.49 to 1.13, P = .18) were also 
reduced, but the confidence intervals were wide and the associations 
were not statistically significant (data not shown in tables 2–4). An 
adjusted logistic regression model was not run for the association 
between unilateral documented previous benign biopsy and 
mammogram sensitivity because there were too few women with 
documented unilateral biopsy who developed cancer.
ROC Analysis
Overall mammography accuracy was examined using two ROC 
analyses to estimate the AUC of the radiologists’ interpretations of 
screening mammograms. First, we found that accuracy was statis-
tically significantly lower for mammograms with a self-reported 
biopsy history (AUC = 0.892) compared with no biopsy history 
(AUC = 0.925) (P < .001). Then, we reran the analysis including 
self-reported (AUC = 0.893) and documented biopsy history 
(AUC = 0.886), compared with no biopsy history (AUC = 0.925), 
and also showed a statistically significant reduction in accuracy 
(P < .001) (Figure 2).
Discussion
To our knowledge, this is the largest analysis investigating the ef-
fect of a previous benign breast biopsy on the interpretive perfor-
mance of screening mammography and accounting for other 
characteristics (age at the time of mammogram, time since last 
mammogram, breast density, availability of comparison film, mam-
mography registry, and year of examination) that affect mammog-
raphy interpretive sensitivity, specificity, PPV 1, PPV2, and overall 
accuracy (AUC). Consistent with our initial hypotheses, a self- 
reported benign breast biopsy history was associated with lower 
specificity, PPV2, and AUC. The findings for specificity and PPV2 
were confirmed in the breast-level analysis, and the reduced odds 
of a correct interpretation were reinforced in analyses using a 
documented biopsy history and when only subsequent invasive 
Table 4. Association between type of biopsy and subsequent mammography performance measures*
Mammography  
performance measures
Documented FNA or cyst  
aspirations,† OR (95% CI)
Documented core  
biopsies,† OR (95% CI)
Documented excisional biopsies,  
surgical biopsy, or not otherwise  
specified,† OR (95% CI) P‡
Sensitivity§ 0.9 (0.55 to 1.47) 1.3 (0.87 to 2.16) 1.2 (0.56 to 3.07) .5306
Specificity║ 0.58 (0.55 to 0.61) 0.69 (0.66 to 0.72) 0.66 (0.61 to 0.71) <.001
PPV1¶ 1.05 (0.82 to 1.31) 1.30 (1.09 to 1.54) 1.17 (0.8 to 1.64) <.05
PPV2# 0.95 (0.70 to 1.28) 0.70 (0.57 to 0.86) 0.99 (0.61 to 1.55) <.01
* Odds ratios (ORs) and 95% confidence intervals (CIs) for a correct interpretation when comparing screening mammograms with prior documented biopsies (fine 
needle aspiration [FNA] or cyst aspiration, core biopsies, excisional biopsies, surgical biopsy, or not otherwise specified) with screening mammograms without a 
biopsy history were computed from multivariable logistic regression models including age at mammogram (in 5-year intervals), months since last mammogram, 
breast density, availability of comparison film, mammography registry, and year of examination as covariates. The model for sensitivity used fewer categories 
for age at mammogram and months since last mammogram and did not include the availability of comparison film because of small numbers. The analysis was 
based on 1 703 328 screens among women without a biopsy history (7119 associated with a subsequent cancer), 13 339 screens among women with a prior 
documented FNA or cyst aspiration (99 associated with a subsequent cancer), 22 889 screens with prior documented core biopsies (167 associated with a  
subsequent cancer), and 7682 screens among women with documented prior excisional biopsies, surgical biopsy, or not otherwise specified (40 associated  
with a subsequent breast cancer). PPV1 = positive predictive value 1; PPV2 = positive predictive value 2.
† Based on biopsies documented in the cancer registries or pathology databases before screening mammograms performed from January 2, 1996, through 
December 31, 2005.
‡ Two-sided P values for overall association of biopsy history with performance measure in the multivariate models were calculated using likelihood ratio tests.
§ Odds of a positive screen (Breast Imaging Reporting and Data System [BI-RADS] = 0, 4, 5, or 3 with recommendation for additional evaluation) among screening 
mammograms from women with a subsequent cancer diagnosis (sensitivity), comparing examinations from women with a documented biopsy (FNA or cyst 
aspirations, core biopsies, excisional biopsies) with screening mammograms from women without a biopsy history.
║ Odds of a negative screen (BI-RADS assessment = 1, 2, or 3 without immediate follow-up) among screening mammograms from women without a subsequent 
cancer diagnosis (specificity), comparing screening mammograms from women with a documented biopsy (FNA or cyst aspirations, core biopsies, excisional 
biopsies) with screening mammograms from women without a biopsy history.
¶ Odds of a subsequent cancer among positive screening mammograms (BI-RADS = 0, 4, 5, or 3 with recommendation for additional evaluation) (PPV1), comparing 
screening mammograms from women with a documented biopsy (FNA or cyst aspirations, core biopsies, excisional biopsies) with screening mammograms from 
women without a biopsy history.
# Odds of a subsequent cancer among screening mammogram with a recommendation for biopsy (BI-RADS assessment = 4, 5) (PPV2), comparing screening 
mammograms from women with a documented biopsy (FNA or cyst aspirations, core biopsies, excisional biopsies) with screening mammograms from women 
without a biopsy history.
Figure 2. Area under the receiver operating curve (AUC) for screening 
examinations associated with a biopsy history (yes vs no). Yes = self-
reported biopsy history or biopsy tissue in the pathology database. 
No = no biopsy history.
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cancers were included. Sensitivity was not statistically significantly 
reduced based on either the self-reported or the documented bi-
opsy history at the woman-level or breast-level analysis.
When documented biopsy history was examined, the associa-
tion was contrary to our hypotheses—mammogram sensitivity 
was higher among women with core or excisional biopsies com-
pared with less intrusive procedures like FNA. Therefore, it 
cannot be concluded that the biopsy itself affected sensitivity or 
was the cause for the observed difference in performance. 
Furthermore, when we evaluated specificity among women with 
known types of benign biopsy procedures, we found that the least 
intrusive biopsy technique was associated with the lowest mam-
mogram specificity. This suggests that the intrinsic characteristics 
of the breast tissue, such as fibrocystic change or fibroglandular 
breast structure, may be responsible for interpretive differences 
and the biopsy history is an associated epiphenomenon. Therefore, 
we conclude that self-reported benign breast biopsy history is as-
sociated with lower mammography performance, although the 
difference is likely because of tissue characteristics rather than the 
biopsy itself. These findings can be used by clinicians to inform 
women that they are more likely to have a false-positive subse-
quent mammographic examination if they have a breast biopsy 
than if they do not have a biopsy. The clinicians can also inform 
the patients that it is unlikely that the biopsy itself will affect sub-
sequent cancer detection.
Consistent with other work, we also demonstrate that women 
with a benign biopsy history are recalled for additional imaging 
more frequently (+2.5%) than women without such a history (29). 
Slanetz et al. (10) report a 1% difference in recall in their retro-
spective analysis of women with a biopsy history. The impact of a 
1%–3% difference in recall can be estimated for women in the 
United States (n = 132 489 248 women, aged >40 years, based on 
US Census estimates) assuming that 66% have been screened (n = 
87 442 903) and half of these women (n = 43 721 452) were screened 
in each of the previous 2 years. If we use these numbers for 
the total screened population and assume that 14.6% will have a 
biopsy history and that a 1%–3% increase in the recall rate is asso-
ciated with this biopsy history, then between 63 833 (0.146 × 
43 721 452 × 0.01) and 191 500 (0.146 × 43 721 452 × 0.03) addi-
tional women will be recalled each year in the United States by 
virtue of having a previous benign biopsy.
The complexity of interpreting our findings lies in how to 
interpret the associations between biopsy history and subsequent 
mammography sensitivity. The odds ratio for detection is reduced 
after a negative biopsy, but the difference is small and not statisti-
cally significant. We found a 2.7% reduced unadjusted sensitivity 
among women with a biopsy vs no biopsy (79.6% vs 82.3%). Banks 
et al. (12) reported a 5.6% difference in unadjusted sensitivity 
among women with a history of benign biopsy compared with 
those with no prior benign biopsy (83.5% vs 89.1%), although the 
reduction was not statistically significant. Unlike the study by 
Banks et al. (12), we were able to control for additional factors 
expected to be associated with performance, such as breast density 
and months since last examination. The difference in sensitivity 
was marginally but not statistically significant for the overall asso-
ciation. Whereas a larger set of cancers might demonstrate an 
unadjusted difference, the dataset used in our study included a 
large number of cancers and other data that allowed adjustment for 
factors confounding the association. The lack of statistical signifi-
cance is important in the adjusted analysis, and the apparent 
reduced sensitivity among women with a previous benign biopsy 
reported in the previous unadjusted analysis is a limitation of 
observational studies.
Furthermore, the meaning of self-reported biopsy history has 
changed with time, so interpretation of its effect may have changed 
as well. For example, based on our pathology database, a much 
higher proportion of women had a core biopsy in 2003 (71.8%) 
than in 1996 (34.8%). In our main multivariable analysis, we tested 
for the differential effects of biopsy over time by testing an inter-
action term for calendar year and biopsy but did not see an associ-
ation. In this analysis, we assumed a constant effect of each biopsy 
type over time. But since the distribution of biopsy types changed 
and we did not find differential effect of biopsy across calendar 
years, it was reasonable to conclude that the effect, if any, was 
small. Using the database of known biopsies, we were able to also 
show that core and excisional biopsies were associated with similar 
and not reduced sensitivity. Therefore, we concluded that the dif-
ference in mammography performance in women with previous 
breast biopsies was not because of biopsy techniques. An alterna-
tive explanation is that the differences in the mammography per-
formance were because of intrinsic breast parenchymal patterns 
that resulted in the original negative biopsy. Because many factors 
cause changes in the breast tissue, it remains to be seen what fac-
tors contribute to changes that result in cancer and how they are 
associated with images that merit biopsy.
Because there can be a trade-off between sensitivity and 
specificity, we also used a single measure of accuracy—the area 
under the receiver operating curve (AUC). This analysis evalu-
ates the ability of the radiologist to discriminate between 
healthy and diseased tissue by relating sensitivity to specificity 
and accounting for differences in the threshold for a positive 
interpretation (18). It is plausible that radiologists would lower 
their threshold for requesting additional evaluation or biopsy if 
women had a biopsy history but that should not change the 
AUC. Because we observed a reduced AUC in the presence of a 
documented or self-reported biopsy, our results demonstrate 
that interpretive performance in a biopsied woman appears to 
be different and less accurate than in an unbiopsied woman. 
Our findings regarding sensitivity and specificity suggest that 
specificity is the main cause of the difference in overall accuracy 
because it is persistently and significantly lower in examinations 
among previously biopsied women.
There are several potential limitations of this study including 
the use of self-reported biopsy information. Self-reported biopsy 
may be inaccurate, or information on the specific location of the 
biopsy within the breast may not be recorded and analyzed. In the 
main woman-level analysis, we do not know if the subsequent 
mammography performance was a result of changes at the location 
of the biopsy or a finding in another quadrant of the same breast 
or the other unbiopsied breast. We did not have information at the 
individual woman level regarding whether the mammogram was 
interpreted with the use of computer-assisted detection (CAD) or 
whether digital technology was used. However, because our 
analyses adjusted for the year of mammogram and we did not find 
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a biopsy effect that differed by year, we do not think the effects of 
digital mammography and CAD affected our conclusions.
Radiologists may also wonder about the use of BI-RADS 3+ 
interpretation because it does not appear in practice. It was used 
in our study to be consistent with the intent of BI-RADS to 
reflect an increasing level of concern, and as demonstrated else-
where (22), the likelihood of cancer increases between BI-RADS 
2, 3, and 3+. We included the 3+ category for analytic purposes 
to capture those mammography interpretations associated with a 
recommendation for additional imaging that was not recorded. 
Including all, the BI-RADS 3+ as a negative examination would 
underestimate the interpretive skills of the radiologist at the initial 
interpretation.
Also, there may be concerns that we identified the cancer status 
differentially among biopsied and unbiopsied women. However, 
our breast-level analysis found nearly identical results as the 
finding of reduced interpretive performance at the woman-level. 
However, in the breast-level analysis we used the biopsied and 
unbiopsied breasts of the same women. This within-woman 
analysis provides reassurance that the results are valid and not 
because of differential reporting or a spurious association in the 
woman-level analysis.
Throughout the time course of this study, many practices such 
as the use of CAD and the more common use of core biopsies have 
changed. We pointed out the increasing use of core biopsy and 
accounted for the year of mammogram in the analysis. The year of 
the mammogram was statistically significantly associated with per-
formance measures, suggesting that those measures changed over 
time. We also tested the interaction between the year of mammo-
gram and self-reported biopsy and did not find an association with 
the mammography performance measures. This result suggests 
that the reported effect of biopsy did not change over the period of 
the study. Factors that could have affected performance include 
the learning curve of the radiologist, the addition of CAD, im-
provements in technology, and the addition of double reading (two 
separate people reading the same mammogram) (30). None of 
these effects were accounted for in our analysis, but we do not 
think that they would alter our conclusions because we examined 
whether the association between mammography performance and 
history of biopsy changed with time and found no differential 
effects over time.
We believe that the reduced accuracy reported in this study is 
clinically important, regardless of whether the biopsy caused the 
differences, because this will help clinicians inform women about 
the potential adverse effects of benign biopsy. Our results showed 
that the unadjusted specificity was reduced by 2.3 percentage 
points. After adjustment for women’s characteristics, evidence of 
reduced specificity and reduced PPV2 was statistically significant. 
These differences in specificity mean additional imaging evalua-
tions and potentially more biopsies among women with a benign 
biopsy history, but our findings regarding sensitivity make it seem 
unlikely that more cancers were subsequently missed. Thus, our 
results could be used to prepare women with a history of a previous 
benign biopsy when they are being referred for their next mammo-
gram. Although a woman with a previous benign biopsy is more 
likely to have cancer than someone without such a history, it can 
also be noted that she has a higher risk of a false-positive screening 
mammogram. The message before the next mammogram for a 
woman with a benign biopsy history should be that a positive test 
must be taken seriously, but there is also a good chance of a false-
positive test. Furthermore, it is not likely to affect subsequent 
cancer detection. Whether this mitigates anxiety at the time of a 
referral should be studied further because persistent anxiety is the 
principal long-term consequence of a false-positive mammogram 
(31,32).
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